Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
AERI
$15.12
Aerie Pharmaceuticals
($.02)
(.13%)
AERI
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus: ($0.42)
Revenue: $35.53 Mil
Thursday
Nov 3
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, August 4, 2022
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
What do you expect when AERI reports earnings?
Beat
Meet
Miss
Where is AERI's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$15.22
$15.19
$15.15
$15.12
Support
$15.08
$15.05
$15.01
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's lead Dual- Action product and Triple-Action products are under developmental stages. Aerie Pharmaceuticals, Inc. is headquartered in Bedminster, New Jersey.
Peers
Vertex Pharmaceuticals
Regeneron Pharmaceuticals
Merck & Co.
Bristol-Myers Squibb
Johnson & Johnson
Eli Lilly
BioMarin Pharmaceutical
Ultragenyx Pharmaceutical
Pfizer
PTC Therapeutics
Expectations
›
Aerie Pharmaceuticals
